These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1717 related articles for article (PubMed ID: 32429703)

  • 21. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
    Xu J; Shi PY; Li H; Zhou J
    ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of SARS-CoV-2 vaccine candidates.
    Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
    Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
    Li G; De Clercq E
    Nat Rev Drug Discov; 2020 Mar; 19(3):149-150. PubMed ID: 32127666
    [No Abstract]   [Full Text] [Related]  

  • 24. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?
    Elrashdy F; Redwan EM; Uversky VN
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32933047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients.
    Yashavantha Rao HC; Jayabaskaran C
    J Med Virol; 2020 Jul; 92(7):786-790. PubMed ID: 32320066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes.
    Kandeel M; Ibrahim A; Fayez M; Al-Nazawi M
    J Med Virol; 2020 Jun; 92(6):660-666. PubMed ID: 32159237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
    Wang S; Li W; Hui H; Tiwari SK; Zhang Q; Croker BA; Rawlings S; Smith D; Carlin AF; Rana TM
    EMBO J; 2020 Nov; 39(21):e106057. PubMed ID: 32944968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological therapies for patients with human coronavirus infections: a rapid systematic review.
    Andrade KRC; Carvalho VKDS; Farinasso CM; Lima AA; Silva RB; Wachira VK; Capucho HC; Souza PM; Vanni T; Sachetti CG; Rêgo DF
    Cien Saude Colet; 2020 Sep; 25(9):3517-3554. PubMed ID: 32876256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Basis of Pathogenesis of Coronaviruses: A Comparative Genomics Approach to Planetary Health to Prevent Zoonotic Outbreaks in the 21st Century.
    Asrani P; Hasan GM; Sohal SS; Hassan MI
    OMICS; 2020 Nov; 24(11):634-644. PubMed ID: 32940573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronaviruses: An Updated Overview of Their Replication and Pathogenesis.
    Wang Y; Grunewald M; Perlman S
    Methods Mol Biol; 2020; 2203():1-29. PubMed ID: 32833200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the efficacy and safety of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19): A protocol for systematic review and meta-analysis.
    Wang Y; Li W; Jiang Z; Xi X; Zhu Y
    Medicine (Baltimore); 2020 Sep; 99(38):e22379. PubMed ID: 32957417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Déjà vu: Stimulating open drug discovery for SARS-CoV-2.
    Ekins S; Mottin M; Ramos PRPS; Sousa BKP; Neves BJ; Foil DH; Zorn KM; Braga RC; Coffee M; Southan C; Puhl AC; Andrade CH
    Drug Discov Today; 2020 May; 25(5):928-941. PubMed ID: 32320852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.
    Yu C; Kang L; Chen J; Zang N
    Int Immunopharmacol; 2020 Sep; 86():106740. PubMed ID: 32645630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
    Mishra J; Prasun C; Sahoo PK; Nair MS
    Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
    Vargas M; Servillo G; Einav S
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses.
    Abdelrahman Z; Li M; Wang X
    Front Immunol; 2020; 11():552909. PubMed ID: 33013925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What are our pharmacotherapeutic options for MERS-CoV?
    Al-Tawfiq JA; Memish ZA
    Expert Rev Clin Pharmacol; 2014 May; 7(3):235-8. PubMed ID: 24580083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV.
    Singh A; Singh RS; Sarma P; Batra G; Joshi R; Kaur H; Sharma AR; Prakash A; Medhi B
    Virol Sin; 2020 Jun; 35(3):290-304. PubMed ID: 32607866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
    Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
    Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 86.